Skip to content
Back to outputs

A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett’s surveillance: the ABBA trial

Research output: Contribution to journalArticlepeer-review

Standard

A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett’s surveillance: the ABBA trial. / Longcroft-Wheaton, Gaius; Fogg, Carole; Chedgy, Fergus; Kandiah, Kesavan; Murray, Lisa; Dewey, Ann; Barr, Hugh; Higgins, Bernie; Poller, David; Jankowski, Janusz; DeCaestecker, John; Bhandari, Pradeep.

In: Endoscopy, Vol. 52, No. 01, 01.01.2020, p. 29-36.

Research output: Contribution to journalArticlepeer-review

Harvard

Longcroft-Wheaton, G, Fogg, C, Chedgy, F, Kandiah, K, Murray, L, Dewey, A, Barr, H, Higgins, B, Poller, D, Jankowski, J, DeCaestecker, J & Bhandari, P 2020, 'A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett’s surveillance: the ABBA trial', Endoscopy, vol. 52, no. 01, pp. 29-36. https://doi.org/10.1055/a-1015-6653

APA

Longcroft-Wheaton, G., Fogg, C., Chedgy, F., Kandiah, K., Murray, L., Dewey, A., Barr, H., Higgins, B., Poller, D., Jankowski, J., DeCaestecker, J., & Bhandari, P. (2020). A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett’s surveillance: the ABBA trial. Endoscopy, 52(01), 29-36. https://doi.org/10.1055/a-1015-6653

Vancouver

Author

Longcroft-Wheaton, Gaius ; Fogg, Carole ; Chedgy, Fergus ; Kandiah, Kesavan ; Murray, Lisa ; Dewey, Ann ; Barr, Hugh ; Higgins, Bernie ; Poller, David ; Jankowski, Janusz ; DeCaestecker, John ; Bhandari, Pradeep. / A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett’s surveillance: the ABBA trial. In: Endoscopy. 2020 ; Vol. 52, No. 01. pp. 29-36.

Bibtex

@article{17b534eeb4b144508e28fb0dd8606d62,
title = "A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett{\textquoteright}s surveillance: the ABBA trial",
abstract = "Background: The aims of this study were to compare neoplasia detection rates for nontargeted biopsies (Seattle protocol) versus acetic acid-targeted biopsies (Portsmouth protocol) during Barrett{\textquoteright}s surveillance and to explore feasibility, patient/clinician experience, acceptance, and barriers/enablers to study participation and implementation of the acetic acid technique.Methods: This was a mixed-methods feasibility study including a pilot multicenter, randomized, crossover trial with qualitative interviews. Patients under Barrett{\textquoteright}s surveillance with no history of neoplasia were included. Patients underwent two endoscopies, one with each protocol, 8 weeks apart. Outcomes included recruitment and retention rates, neoplasia yield, and number of biopsies.Results: 200 patients were recruited from 6 centers, and 174 (87.0 %) underwent both procedures. Neoplasia prevalence was 4.7 % (9/192). High grade dysplasia and cancer were detected with both protocols. Five low grade dysplasias were detected (two with acetic acid, four with nontargeted biopsies; one lesion was detected with both techniques). A total of 2139 biopsies were taken in the nontargeted arm and 226 in the acetic acid arm. Both patients and clinicians found the acetic acid technique acceptable. Based on these data, a noninferiority, tandem, crossover trial would require an estimated 2828 patients.Conclusions: We demonstrated the feasibility of performing a crossover endoscopy trial in Barrett{\textquoteright}s surveillance. Low neoplasia yield makes this design necessary and qualitative results demonstrated patient and clinician acceptance. The reduced numbers of biopsies suggest that the acetic acid technique could result in cost savings, providing the lack of missed pathology can be proven in a fully powered definitive trial.",
author = "Gaius Longcroft-Wheaton and Carole Fogg and Fergus Chedgy and Kesavan Kandiah and Lisa Murray and Ann Dewey and Hugh Barr and Bernie Higgins and David Poller and Janusz Jankowski and John DeCaestecker and Pradeep Bhandari",
year = "2020",
month = jan,
day = "1",
doi = "10.1055/a-1015-6653",
language = "English",
volume = "52",
pages = "29--36",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg Thieme Verlag",
number = "01",

}

RIS

TY - JOUR

T1 - A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BArrett’s surveillance: the ABBA trial

AU - Longcroft-Wheaton, Gaius

AU - Fogg, Carole

AU - Chedgy, Fergus

AU - Kandiah, Kesavan

AU - Murray, Lisa

AU - Dewey, Ann

AU - Barr, Hugh

AU - Higgins, Bernie

AU - Poller, David

AU - Jankowski, Janusz

AU - DeCaestecker, John

AU - Bhandari, Pradeep

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background: The aims of this study were to compare neoplasia detection rates for nontargeted biopsies (Seattle protocol) versus acetic acid-targeted biopsies (Portsmouth protocol) during Barrett’s surveillance and to explore feasibility, patient/clinician experience, acceptance, and barriers/enablers to study participation and implementation of the acetic acid technique.Methods: This was a mixed-methods feasibility study including a pilot multicenter, randomized, crossover trial with qualitative interviews. Patients under Barrett’s surveillance with no history of neoplasia were included. Patients underwent two endoscopies, one with each protocol, 8 weeks apart. Outcomes included recruitment and retention rates, neoplasia yield, and number of biopsies.Results: 200 patients were recruited from 6 centers, and 174 (87.0 %) underwent both procedures. Neoplasia prevalence was 4.7 % (9/192). High grade dysplasia and cancer were detected with both protocols. Five low grade dysplasias were detected (two with acetic acid, four with nontargeted biopsies; one lesion was detected with both techniques). A total of 2139 biopsies were taken in the nontargeted arm and 226 in the acetic acid arm. Both patients and clinicians found the acetic acid technique acceptable. Based on these data, a noninferiority, tandem, crossover trial would require an estimated 2828 patients.Conclusions: We demonstrated the feasibility of performing a crossover endoscopy trial in Barrett’s surveillance. Low neoplasia yield makes this design necessary and qualitative results demonstrated patient and clinician acceptance. The reduced numbers of biopsies suggest that the acetic acid technique could result in cost savings, providing the lack of missed pathology can be proven in a fully powered definitive trial.

AB - Background: The aims of this study were to compare neoplasia detection rates for nontargeted biopsies (Seattle protocol) versus acetic acid-targeted biopsies (Portsmouth protocol) during Barrett’s surveillance and to explore feasibility, patient/clinician experience, acceptance, and barriers/enablers to study participation and implementation of the acetic acid technique.Methods: This was a mixed-methods feasibility study including a pilot multicenter, randomized, crossover trial with qualitative interviews. Patients under Barrett’s surveillance with no history of neoplasia were included. Patients underwent two endoscopies, one with each protocol, 8 weeks apart. Outcomes included recruitment and retention rates, neoplasia yield, and number of biopsies.Results: 200 patients were recruited from 6 centers, and 174 (87.0 %) underwent both procedures. Neoplasia prevalence was 4.7 % (9/192). High grade dysplasia and cancer were detected with both protocols. Five low grade dysplasias were detected (two with acetic acid, four with nontargeted biopsies; one lesion was detected with both techniques). A total of 2139 biopsies were taken in the nontargeted arm and 226 in the acetic acid arm. Both patients and clinicians found the acetic acid technique acceptable. Based on these data, a noninferiority, tandem, crossover trial would require an estimated 2828 patients.Conclusions: We demonstrated the feasibility of performing a crossover endoscopy trial in Barrett’s surveillance. Low neoplasia yield makes this design necessary and qualitative results demonstrated patient and clinician acceptance. The reduced numbers of biopsies suggest that the acetic acid technique could result in cost savings, providing the lack of missed pathology can be proven in a fully powered definitive trial.

U2 - 10.1055/a-1015-6653

DO - 10.1055/a-1015-6653

M3 - Article

VL - 52

SP - 29

EP - 36

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 01

ER -

ID: 17775554